NCT06956326 (MS_Early_Rehab) is a Phase 2 clinical trial of Intensive rehab in Multiple Sclerosis, sponsored by Lars Hvid.

Who is sponsoring NCT06956326?

NCT06956326 is sponsored by Lars Hvid.

What drugs are being tested in NCT06956326?

Interventions in NCT06956326: Intensive rehab, Usual care.

What condition does NCT06956326 study?

NCT06956326 studies Multiple Sclerosis.

Is NCT06956326 still recruiting?

NCT06956326 is currently recruiting now. Last updated 4 May 2025.

Last reviewed 2025-05-04 · How we verify

NCT06956326: MS_Early_Rehab

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Illuminating New Paths in the Treatment of Multiple Sclerosis Relapses - Early and Specialized Rehabilitation

Recruiting now Phase 2 Last updated 4 May 2025

What this trial tests

Phase 2 trial testing Intensive rehab in Multiple Sclerosis in 64 participants. Currently enrolling.

Timeline

1 May 2025

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	Lars Hvid
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	64
Start date	1 May 2025
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	2 locations across Denmark

Drugs / interventions tested

Intensive rehab
Usual care

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Lars Hvid

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall purpose of this project is to develop and test an infrastructure that can ensure early and specialized rehabilitation for individuals with multiple sclerosis (MS) on their path to recovery from a relapse. If this project proves successful, it can therefore help optimize clinical practice and provide a significant contribution to the treatment of relapsing-remitting sclerosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06956326 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lars Hvid
Last refreshed: 4 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06956326.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing